The annual reports for The Coca-Cola Company and PepsiCo, Inc. are available on their respective websites at http://www.coca-colacompany.com/investors/investors-info-reports-and-financial-information and http://www.pepsico.com/Investors/Annual-Reports-and-Proxy-Information.
The annual reports for The Coca-Cola Company and PepsiCo, Inc. are available on their respective websites at http://www.coca-colacompany.com/investors/investors-info-reports-and-financial-informationand http://www.pepsico.com/Investors/Annual-Reports-and-Proxy-Information.
Refer to the most recent annual reports to find these companies’ financial statements and the accompanying notes to answer the following questions:
- What are the primary lines of business of these two companies as shown in the notes to the financial statements?
- Which company has the dominant position in beverage sales?
- How are inventories for these two companies valued? What methods are used to report inventory? How does their accounting for inventories affect comparability between the two companies?
- How are advertising costs accounted for? Where are deferred advertising costs reported in the financial statements? Using the element definition from the conceptual framework, should these deferred advertising costs be recorded as assets in the balance sheets? Why or why not? If so, what measurement attribute should be used in reporting the asset?
Order This Solution
49051 Millions developed by 10% and working benefit in 2009 was 15012 Millions that developed by 6%. Roche is contributed CHF. 9874 Millions on R&D in 2009. The free trade stream out 2009 was 8893 that was 79% more than 2008. The aggregate representative of Roche are 81507. Out of them 80115 are changeless. The Sales commitment is more from US that is 38% than West Europe that is 28%. Since pharmaceutical advertising exercises impact the endorsing conduct of specialists, it is of most extreme significance to basically dissect the cases made in the limited time material of the medications. The degree to which pharmaceutical organizations advance the benefits of their items and applicable clinical trails give to specialists are not examined in Pakistan. The consequences of the present logical examination demonstrate that untrustworthy and one-sided claims with respect to the pharmaceutical items are uncontrolled in Pakistan. These medication advancements impact the recommending conduct of the General Practitioners, Consultants in this manner representing one of the possibly significant reasons for outlandish solution. Roche Pakistan Ltd is a Member of IFPMA and PMA and take after their moral business rules to offer its items. Roche Paksitan Ltd is at sixth positioning in Pakistan Pharmaceutical Market and its yearly deal is Rs. 5.2 Billions out of 2009 in Pakistan.>GET ANSWER